{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:21:00Z","timestamp":1794900060864,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA241810"],"award-info":[{"award-number":["R01CA241810"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA292625"],"award-info":[{"award-number":["R01CA292625"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The APOBEC3 family of RNA and single stranded DNA cytidine deaminases contribute prominently to the mutagenesis of certain cancers including urothelial carcinoma of the bladder (UC). Remarkably, up to 70% of mutations in UC are attributable to the mutagenic activity of the APOBEC3 deaminases. Despite this strong association, few functional studies have investigated APOBEC3\u2019s role in bladder cancer. We report a genetically engineered murine model with conditional knock out of\n                    <jats:italic>Pten<\/jats:italic>\n                    and\n                    <jats:italic>Trp53<\/jats:italic>\n                    in addition to overexpression of mouse Apobec3 (UPPA). Analysis of bladder tumors from UPPA mice demonstrates that mA3 promotes tumor progression and squamous trans-differentiation. We establish that APOBEC3 promotes squamous differentiation through IL-1\u03b1 and downstream activation of the AP-1 transcription factor. Bulk RNA-sequencing from human UC shows\n                    <jats:italic>APOBEC3A<\/jats:italic>\n                    as the only human APOBEC3 family member to correlate with squamous differentiation. Furthermore, single cell and spatial transcriptomics reinforces the role of\n                    <jats:italic>APOBEC3A<\/jats:italic>\n                    in fostering squamous trans-differentiation and promoting the emergence of a subpopulation of highly squamous epithelial cells. Our results demonstrate that mouse Apobec3 and human APOBEC3A promote squamous differentiation in urothelial carcinoma and that this trans-differentiation phenotype is mediated through IL-1\u03b1 signaling, a target of FDA approved therapies for rheumatologic disease.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-67033-8","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T02:54:43Z","timestamp":1765680883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["APOBEC3 promotes squamous differentiation via IL-1A\/AP-1 signaling"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-2275","authenticated-orcid":false,"given":"Michael S.","family":"Sturdivant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8144-3468","authenticated-orcid":false,"given":"Mi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott D.","family":"Toomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Beckabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Raupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujjawal","family":"Manocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibardo A.","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Jui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Bjurlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-8129","authenticated-orcid":false,"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Wobker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn H.","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-0285","authenticated-orcid":false,"given":"Jeffrey S.","family":"Damrauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2156","authenticated-orcid":false,"given":"William Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"key":"67033_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"67033_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5489\/cuaj.1195","volume":"3","author":"V Chalasani","year":"2013","unstructured":"Chalasani, V., Chin, J. L. & Izawa, J. I. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can. Urol. Assoc. J. 3, 193\u2013198 (2013).","journal-title":"Can. Urol. Assoc. J."},{"key":"67033_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.eururo.2025.04.008","volume":"88","author":"CE Chu","year":"2025","unstructured":"Chu, C. E. et al. Clinical outcomes, genomic heterogeneity, and therapeutic considerations across histologic subtypes of urothelial carcinoma. Eur. Urol. 88, 472\u2013481 (2025).","journal-title":"Eur. Urol."},{"key":"67033_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/107327481702400113","volume":"24","author":"Y Liu","year":"2017","unstructured":"Liu, Y., Bui, M. M. & Xu, B. Urothelial carcinoma with squamous differentiation is associated with high tumor stage and pelvic lymph-node metastasis. Cancer Control 24, 78\u201382 (2017).","journal-title":"Cancer Control"},{"key":"67033_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34251-3","volume":"13","author":"JI Warrick","year":"2022","unstructured":"Warrick, J. I. et al. FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation. Nat. Commun. 13, 6575 (2022).","journal-title":"Nat. Commun."},{"key":"67033_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"JN Weinstein","year":"2014","unstructured":"Weinstein, J. N. et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315\u2013322 (2014).","journal-title":"Nature"},{"key":"67033_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33980-9","volume":"13","author":"JS Damrauer","year":"2022","unstructured":"Damrauer, J. S. et al. Collaborative study from the bladder cancer advocacy network for the genomic analysis of metastatic urothelial cancer. Nat. Commun. 13, 6658 (2022).","journal-title":"Nat. Commun."},{"key":"67033_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev-genet-072920-035840","volume":"56","author":"TM Mertz","year":"2022","unstructured":"Mertz, T. M., Collins, C. D., Dennis, M., Coxon, M. & Roberts, S. A. APOBEC-induced mutagenesis in cancer. Annu. Rev. Genet. 56, 229\u2013252 (2022).","journal-title":"Annu. Rev. Genet."},{"key":"67033_CR9","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/ng.2702","volume":"45","author":"SA Roberts","year":"2013","unstructured":"Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970\u2013976 (2013).","journal-title":"Nat. Genet."},{"key":"67033_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrc3816","volume":"14","author":"SA Roberts","year":"2014","unstructured":"Roberts, S. A. & Gordenin, D. A. Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer 14, 786\u2013800 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"67033_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature11881","volume":"494","author":"MB Burns","year":"2013","unstructured":"Burns, M. B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366\u2013370 (2013).","journal-title":"Nature"},{"key":"67033_CR12","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/ng.2701","volume":"45","author":"MB Burns","year":"2013","unstructured":"Burns, M. B., Temiz, N. A. & Harris, R. S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977\u2013983 (2013).","journal-title":"Nat. Genet."},{"key":"67033_CR13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200261","volume":"217","author":"EK Law","year":"2020","unstructured":"Law, E. K. et al. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo. J. Exp. Med. 217, e20200261 (2020).","journal-title":"J. Exp. Med."},{"key":"67033_CR14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1080\/15384101.2016.1152426","volume":"15","author":"AM Green","year":"2016","unstructured":"Green, A. M. et al. APOBEC3A damages the cellular genome during DNA replication. Cell Cycle 15, 998\u20131008 (2016).","journal-title":"Cell Cycle"},{"key":"67033_CR15","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.celrep.2015.09.077","volume":"13","author":"MD Kazanov","year":"2015","unstructured":"Kazanov, M. D. et al. APOBEC-induced cancer mutations are uniquely enriched in early-replicating, gene-dense, and active chromatin regions. Cell Rep. 13, 1103\u20131109 (2015).","journal-title":"Cell Rep."},{"key":"67033_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"67033_CR17","doi-asserted-by":"publisher","first-page":"22158","DOI":"10.1073\/pnas.1904024116","volume":"116","author":"AA Serebrenik","year":"2019","unstructured":"Serebrenik, A. A. et al. The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase. Proc. Natl. Acad. Sci. USA 116, 22158\u201322163 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67033_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41586-022-04972-y","volume":"607","author":"M Petljak","year":"2022","unstructured":"Petljak, M. et al. Mechanisms of APOBEC3 mutagenesis in human cancer cells. Nature 607, 799\u2013807 (2022).","journal-title":"Nature"},{"key":"67033_CR19","doi-asserted-by":"publisher","unstructured":"Liu, W. et al. The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.can-22-2912 (2022).","DOI":"10.1158\/0008-5472.can-22-2912"},{"key":"67033_CR20","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/ng.3670","volume":"48","author":"CD Middlebrooks","year":"2016","unstructured":"Middlebrooks, C. D. et al. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat. Genet. 48, 1330\u20131338 (2016).","journal-title":"Nat. Genet."},{"key":"67033_CR21","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1158\/0008-5472.CAN-18-0173","volume":"78","author":"R Saito","year":"2018","unstructured":"Saito, R. et al. Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Res. 78, 3954\u20133968 (2018).","journal-title":"Cancer Res."},{"key":"67033_CR22","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e21 (2019).","journal-title":"Cell"},{"key":"67033_CR23","doi-asserted-by":"publisher","first-page":"eaba7721","DOI":"10.1126\/science.aba7721","volume":"370","author":"J Cao","year":"2020","unstructured":"Cao, J. et al. A human cell atlas of fetal gene expression. Science 370, eaba7721 (2020).","journal-title":"Science"},{"key":"67033_CR24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI169241","volume":"134","author":"A Okato","year":"2024","unstructured":"Okato, A. et al. FGFR inhibition augments anti\u2013PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression. J. Clin. Investig. 134, e169241 (2024).","journal-title":"J. Clin. Investig."},{"key":"67033_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12307-1","volume":"10","author":"CP Santos","year":"2019","unstructured":"Santos, C. P. et al. Urothelial organoids originating from Cd49fhigh mouse stem cells display Notch-dependent differentiation capacity. Nat. Commun. 10, 4407 (2019).","journal-title":"Nat. Commun."},{"key":"67033_CR26","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1073\/pnas.1803595116","volume":"116","author":"J Mullenders","year":"2019","unstructured":"Mullenders, J. et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research. Proc. Natl. Acad. Sci. USA 116, 4567\u20134574 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67033_CR27","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ncb1909","volume":"11","author":"F Rodier","year":"2009","unstructured":"Rodier, F. et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 11, 973\u2013979 (2009).","journal-title":"Nat. Cell Biol."},{"key":"67033_CR28","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.53381","volume":"9","author":"TD Somerville","year":"2020","unstructured":"Somerville, T. D. et al. Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. eLife 9, e53381 (2020).","journal-title":"eLife"},{"key":"67033_CR29","doi-asserted-by":"publisher","first-page":"722676","DOI":"10.3389\/froh.2021.722676","volume":"2","author":"SE Niklander","year":"2021","unstructured":"Niklander, S. E., Murdoch, C. & Hunter, K. D. IL-1\/IL-1R signaling in head and neck cancer. Front. Oral. Health 2, 722676 (2021).","journal-title":"Front. Oral. Health"},{"key":"67033_CR30","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/ni.3503","volume":"17","author":"NCD Paolo","year":"2016","unstructured":"Paolo, N. C. D. & Shayakhmetov, D. M. Interleukin 1\u03b1 and the inflammatory process. Nat. Immunol. 17, 906\u2013913 (2016).","journal-title":"Nat. Immunol."},{"key":"67033_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep14756","volume":"5","author":"I Cohen","year":"2015","unstructured":"Cohen, I. et al. IL-1\u03b1 is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity. Sci. Rep. 5, 14756 (2015).","journal-title":"Sci. Rep."},{"key":"67033_CR32","doi-asserted-by":"publisher","first-page":"37398","DOI":"10.18632\/oncotarget.6054","volume":"6","author":"X Le\u00f3n","year":"2015","unstructured":"Le\u00f3n, X. et al. Expression of IL-1\u03b1 correlates with distant metastasis in patients with head and neck squamous cell carcinoma. Oncotarget 6, 37398\u201337409 (2015).","journal-title":"Oncotarget"},{"key":"67033_CR33","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/s43018-021-00268-8","volume":"2","author":"SM W\u00f6rmann","year":"2021","unstructured":"W\u00f6rmann, S. M. et al. APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Nat. Cancer 2, 1338\u20131356 (2021).","journal-title":"Nat. Cancer"},{"key":"67033_CR34","doi-asserted-by":"publisher","first-page":"e00168","DOI":"10.1128\/JVI.00168-18","volume":"92","author":"S Stavrou","year":"2018","unstructured":"Stavrou, S., Zhao, W., Blouch, K. & Ross, S. R. Deaminase-dead mouse APOBEC3 is an in vivo retroviral restriction factor. J. Virol. 92, e00168\u201318 (2018).","journal-title":"J. Virol."},{"key":"67033_CR35","doi-asserted-by":"publisher","first-page":"7096","DOI":"10.1093\/nar\/gkm750","volume":"35","author":"Y Iwatani","year":"2007","unstructured":"Iwatani, Y. et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35, 7096\u20137108 (2007).","journal-title":"Nucleic Acids Res."},{"key":"67033_CR36","doi-asserted-by":"publisher","first-page":"10881","DOI":"10.1038\/s41598-017-11344-4","volume":"7","author":"Y Feng","year":"2017","unstructured":"Feng, Y., Goubran, M. H., Follack, T. B. & Chelico, L. Deamination-independent restriction of LINE-1 retrotransposition by APOBEC3H. Sci. Rep. 7, 10881 (2017).","journal-title":"Sci. Rep."},{"key":"67033_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109774","volume":"37","author":"F Kuonen","year":"2021","unstructured":"Kuonen, F. et al. c-FOS drives reversible basal to squamous cell carcinoma transition. Cell Rep. 37, 109774 (2021).","journal-title":"Cell Rep."},{"key":"67033_CR38","doi-asserted-by":"publisher","first-page":"7578","DOI":"10.1158\/0008-5472.CAN-06-1247","volume":"66","author":"MJ Gerdes","year":"2006","unstructured":"Gerdes, M. J. et al. Activator protein-1 activity regulates epithelial tumor cell identity. Cancer Res. 66, 7578\u20137588 (2006).","journal-title":"Cancer Res."},{"key":"67033_CR39","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/0092-8674(95)90469-7","volume":"82","author":"E Saez","year":"1995","unstructured":"Saez, E. et al. c-fos is required for malignant progression of skin tumors. Cell 82, 721\u2013732 (1995).","journal-title":"Cell"},{"key":"67033_CR40","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl. Acad. Sci. USA 111, 3110\u20133115 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67033_CR41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).","journal-title":"Cancer Cell"},{"key":"67033_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12332-0","volume":"10","author":"C Liu","year":"2019","unstructured":"Liu, C. et al. Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells. Nat. Commun. 10, 4589 (2019).","journal-title":"Nat. Commun."},{"key":"67033_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3464","volume":"4","author":"MNC Fletcher","year":"2013","unstructured":"Fletcher, M. N. C. et al. Master regulators of FGFR2 signalling and breast cancer risk. Nat. Commun. 4, 2464 (2013).","journal-title":"Nat. Commun."},{"key":"67033_CR44","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556.e25 (2017).","journal-title":"Cell"},{"key":"67033_CR45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.celrep.2018.03.063","volume":"23","author":"JD Campbell","year":"2018","unstructured":"Campbell, J. D. et al. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep. 23, 194\u2013212.e6 (2018).","journal-title":"Cell Rep."},{"key":"67033_CR46","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2019)."},{"key":"67033_CR47","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cell.2019.02.012","volume":"176","author":"M Petljak","year":"2019","unstructured":"Petljak, M. et al. Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis. Cell 176, 1282\u20131294.e20 (2019).","journal-title":"Cell"},{"key":"67033_CR48","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","volume":"174","author":"AG Robertson","year":"2018","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 174, 1033 (2018).","journal-title":"Cell"},{"key":"67033_CR49","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","volume":"32","author":"CD Hurst","year":"2017","unstructured":"Hurst, C. D. et al. Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell 32, 701\u2013715.e7 (2017).","journal-title":"Cancer Cell"},{"key":"67033_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard, J. et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30, 27\u201342 (2016).","journal-title":"Cancer Cell"},{"key":"67033_CR51","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.18632\/oncotarget.23344","volume":"9","author":"AP Glaser","year":"2017","unstructured":"Glaser, A. P. et al. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response. Oncotarget 9, 4537\u20134548 (2017).","journal-title":"Oncotarget"},{"key":"67033_CR52","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/ng.3692","volume":"48","author":"BM Faltas","year":"2016","unstructured":"Faltas, B. M. et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat. Genet. 48, 1490\u20131499 (2016).","journal-title":"Nat. Genet."},{"key":"67033_CR53","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/embor.2011.46","volume":"12","author":"S Landry","year":"2011","unstructured":"Landry, S., Narvaiza, I., Linfesty, D. C. & Weitzman, M. D. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep. 12, 444\u2013450 (2011).","journal-title":"EMBO Rep."},{"key":"67033_CR54","doi-asserted-by":"publisher","first-page":"762","DOI":"10.4161\/cc.23713","volume":"12","author":"L Lackey","year":"2013","unstructured":"Lackey, L., Law, E. K., Brown, W. L. & Harris, R. S. Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle 12, 762\u2013772 (2013).","journal-title":"Cell Cycle"},{"key":"67033_CR55","doi-asserted-by":"publisher","first-page":"105073","DOI":"10.1016\/j.jbc.2023.105073","volume":"299","author":"C Wick","year":"2023","unstructured":"Wick, C. et al. Mitochondrial double-stranded RNA triggers induction of the antiviral DNA deaminase APOBEC3A and nuclear DNA damage. J. Biol. Chem. 299, 105073 (2023).","journal-title":"J. Biol. Chem."},{"key":"67033_CR56","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1073\/pnas.1009687108","volume":"108","author":"R Susp\u00e8ne","year":"2011","unstructured":"Susp\u00e8ne, R. et al. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc. Natl. Acad. Sci. USA 108, 4858\u20134863 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67033_CR57","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/j.1349-7006.2011.01887.x","volume":"102","author":"T Shukuya","year":"2011","unstructured":"Shukuya, T. et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci. 102, 1032\u20131037 (2011).","journal-title":"Cancer Sci."},{"key":"67033_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.lungcan.2018.11.027","volume":"127","author":"S Park","year":"2019","unstructured":"Park, S., Han, J. & Sun, J.-M. Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor. Lung Cancer 127, 66\u201368 (2019).","journal-title":"Lung Cancer"},{"key":"67033_CR59","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/j.cllc.2017.10.005","volume":"19","author":"H Izumi","year":"2018","unstructured":"Izumi, H. et al. Squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma: a case report and literature review. Clin. Lung Cancer 19, e63\u2013e66 (2018).","journal-title":"Clin. Lung Cancer"},{"key":"67033_CR60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.6004\/jnccn.2019.7291","volume":"17","author":"J Gong","year":"2019","unstructured":"Gong, J. et al. Squamous cell transformation of primary lung adenocarcinoma in a patient with EML4-ALK fusion variant 5 refractory to ALK inhibitors. J. Natl Compr. Canc Netw. 17, 297\u2013301 (2019).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"67033_CR61","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"67033_CR62","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544\u2013554 (2017).","journal-title":"Eur. Urol."},{"key":"67033_CR63","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00209","volume":"8","author":"K Holmsten","year":"2024","unstructured":"Holmsten, K. et al. Molecular subtypes are associated with clinical benefit in cisplatin-treated metastatic urothelial cancer patients. JCO Precis. Oncol. 8, e2400209 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"67033_CR64","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2326-6066.CIR-21-0146","volume":"10","author":"AV DiMarco","year":"2021","unstructured":"DiMarco, A. V. et al. APOBEC mutagenesis inhibits breast cancer growth through induction of T cell-mediated antitumor immune responses. Cancer Immunol. Res. 10, 70\u201386 (2021).","journal-title":"Cancer Immunol. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67033-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:03:20Z","timestamp":1767967400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67033-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67033"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67033-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]},"assertion":[{"value":"20 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"334"}}